We spoke with Dr. Sara Tolaney, BCRF investigator and 2025 AACR Outstanding Investigator Award for Breast Cancer Research recipient, at #SABCS25 to unpack key research advances from the conference. Here, she breaks down promising updates on oral SERDs for metastatic hormone receptor–positive breast cancer, including FDA-approved Imlunestrant for ESR1-mutant disease, and emerging evidence that oral SERDs—alone or in combination—may help patients live longer while effectively controlling their can

392K views · 188 reactions | Fatigue is a common warning sign of metastatic breast cancer. See what symptoms should be caught early and the treatment options available. | Nation.com | Facebook